Ingrid Hoos
General Counsel bei ETON PHARMACEUTICALS, INC.
Aktive Positionen von Ingrid Hoos
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ETON PHARMACEUTICALS, INC. | General Counsel | - | - |
Karriereverlauf von Ingrid Hoos
Ehemalige bekannte Positionen von Ingrid Hoos
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Baxter Healthcare, Inc. | Corporate Officer/Principal | - | - |
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | General Counsel | - | - |
Ausbildung von Ingrid Hoos
Northeastern Illinois University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
General Counsel | 2 |
Undergraduate Degree | 1 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ETON PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | Health Technology |
Baxter Healthcare, Inc. |
- Börse
- Insiders
- Ingrid Hoos
- Erfahrung